Orphazyme ApS - Product Pipeline Review - 2015

01:13 EDT 15 Apr 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Orphazyme ApS - Product Pipeline Review - 2015 is a new report from Global Markets Direct published on 2015-03-10. This 25-page report is available in PDF from $1500.

Orphazyme ApS - Product Pipeline Review - 2015


Global Markets Direct’s, ‘Orphazyme ApS - Product Pipeline Review - 2015’, provides an overview of the Orphazyme ApS’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Orphazyme ApS’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides brief overview of Orphazyme ApS including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Orphazyme ApS’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Orphazyme ApS’s pipeline products

Reasons to buy

- Evaluate Orphazyme ApS’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Orphazyme ApS in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Orphazyme ApS’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Orphazyme ApS and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to…

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Orphazyme ApS Snapshot 4
Orphazyme ApS Overview 4
Key Information 4
Key Facts 4
Orphazyme ApS - Research and Development Overview 5
Key Therapeutic Areas 5
Orphazyme ApS - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Orphazyme ApS - Pipeline Products Glance 9
Orphazyme ApS - Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Phase I Products/Combination Treatment Modalities 10
Orphazyme ApS - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Orphazyme ApS - Drug Profiles 12
arimoclomol 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
Orph-002 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
OR-0005 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Orph-001 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Orphazyme ApS - Pipeline Analysis 17
Orphazyme ApS - Pipeline Products by Target 17
Orphazyme ApS - Pipeline Products by Route of Administration 18
Orphazyme ApS - Pipeline Products by Molecule Type 19
Orphazyme ApS - Pipeline Products by Mechanism of Action 20
Orphazyme ApS - Recent Pipeline Updates 21
Orphazyme ApS - Dormant Projects 22
Orphazyme ApS - Locations And Subsidiaries 23
Head Office 23
Appendix 24
Methodology 24
Coverage 24
Secondary Research 24
Primary Research 24
Expert Panel Validation 24
Contact Us 24
Disclaimer 25

For more information open Orphazyme ApS - Product Pipeline Review - 2015.


Original Article: Orphazyme ApS - Product Pipeline Review - 2015


More From BioPortfolio on "Orphazyme ApS - Product Pipeline Review - 2015"

Quick Search


Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...